Crossmark

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Crossref DOI link: https://doi.org/10.1186/s13046-018-0702-x

Published Online: 2018-03-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Allegretti, Matteo

Fabi, Alessandra

Buglioni, Simonetta

Martayan, Aline

Conti, Laura

Pescarmona, Edoardo

Ciliberto, Gennaro

Giacomini, Patrizio https://orcid.org/0000-0001-6109-1709
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro (Nuvenia Fellowship id. 19503)

Associazione Italiana per la Ricerca sul Cancro (IG id. 14204)

Associazione Italiana per la Ricerca sul Cancro (IG id. 19052)

Horizon 2020 Framework Programme (Grant Agreement n. 633937)
More Information

Article History

Received: 17 January 2018

Accepted: 6 February 2018

First Online: 5 March 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.